Damora Therapeutics (DMRA) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 17, 2026, with voting on director elections, executive compensation, advisory vote frequency, and auditor ratification.

• Only stockholders of record as of April 22, 2026, are entitled to vote; 60,303,212 shares are outstanding, each with one vote.

• The company transitioned its name and ticker symbol in March 2026 following a November 2025 acquisition.

• Proxy materials are distributed electronically to reduce costs and environmental impact.

Voting matters and shareholder proposals

• Stockholders will vote on electing two Class III directors for a three-year term, approving executive compensation (say-on-pay), the frequency of future say-on-pay votes, and ratifying Ernst & Young LLP as the independent auditor for 2026.

• The board recommends voting for all proposals and for annual (one-year) frequency on say-on-pay votes.

• Stockholders can submit proposals for the 2027 meeting between February 17 and March 19, 2027.

Board of directors and corporate governance

• The board consists of six directors divided into three classes, with staggered three-year terms.

• All directors except the CEO are independent under Nasdaq and SEC rules.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, each with written charters and composed solely of independent directors.

• The board encourages director attendance at meetings and annual meetings; most directors attended at least 75% of meetings in 2025.

• The board chair is independent, and the board regularly holds executive sessions without management.